TH
ALXN

Timber Hill’s Alexion Pharmaceuticals ALXN Stock Holding History

Timber Hill’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,200
Closed -$2.45M – 1965
2017
Q1 		$2.45M Sell
20,200
-800
-4% -$103K 0.02% 618
2016
Q4 		$2.57M Sell
21,000
-14,600
-41% -$1.79M 0.01% 776
2016
Q3 		$4.36M Sell
35,600
-53,600
-60% -$6.9M 0.02% 522
2016
Q2 		$10.4M Buy
89,200
+33,300
+60% +$4.72M 0.05% 310
2016
Q1 		$7.78M Buy
55,900
+17,600
+46% +$2.58M 0.04% 381
2015
Q4 		$7.31M Sell
38,300
-21,000
-35% -$3.67M 0.04% 413
2015
Q3 		$9.27M Sell
59,300
-22,700
-28% -$4.14M 0.04% 346
2015
Q2 		$14.8M Buy
82,000
+16,200
+25% +$2.8M 0.07% 255
2015
Q1 		$11.4M Sell
65,800
-1,500
-2% -$272K 0.05% 305
2014
Q4 		$12.5M Buy
67,300
+15,700
+30% +$2.91M 0.05% 287
2014
Q3 		$8.56M Buy
51,600
+8,600
+20% +$1.41M 0.04% 397
2014
Q2 		$6.72M Sell
43,000
-24,400
-36% -$3.85M 0.03% 487
2014
Q1 		$10.3M Buy
67,400
+21,800
+48% +$3.47M 0.04% 341
2013
Q4 		$6.06M Sell
45,600
-1,600
-3% -$192K 0.02% 665
2013
Q3 		$5.48M Sell
47,200
-15,300
-24% -$1.68M 0.02% 797
2013
Q2 		$5.76M Buy
+62,500
New +$6.02M 0.02% 741

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Timber Hill's ALXN Position: Q2 2018 in Review

Timber Hill sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,953 shares — an estimated $329K sold.

Timber Hill first reported a position in ALXN in Q2 2013 and held it in 6 quarters. The position peaked at $3.81M in Q3 2013. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Timber Hill reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Timber Hill sold 2,953 Alexion Pharmaceuticals shares in Q2 2018, an estimated $329K.
  • Timber Hill first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Timber Hill's Alexion Pharmaceuticals position peaked at $3.81M in Q3 2013.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.